Introduction {#S0001}
============

Diabetes or diabetes mellitus is referred to as a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia and carbohydrate, fat and protein metabolism disorders that result from a defect in the secretion of insulin, or impairment in its function, or both. Types of diabetes mellitus include type 1, type 2 diabetes and other kind of diabetes, but the two most common types of diabetes mellitus are type 1 and type 2, which are different in several aspects.[@CIT0001],[@CIT0002] Type 1 diabetes has been identified with autoimmune destruction of pancreatic beta cells (insulin secreting cells) and accounts for about 5% of all diabetic people, while type 2 diabetes mellitus (T2DM) is a predominant disorder characterized by insulin resistance or a relative decline in insulin production, and accounts for about 90% of all types of diabetes mellitus[@CIT0003] Important factors that predispose a person to T2DM are multifactorial, including genetic factors and environments. However, its inheritance has certainly not been proven, but it is believed that first-degree relatives of diabetic patients have a higher chance to develop the disease. In this regard, recognizing gen polymorphisms of this disease seems to be necessary[@CIT0004]

Multiple genes have been studied in the pathogenesis of T2DM. One of these genes associated with T2DM is the *IRS1* gene (accession number. 147545).[@CIT0005]--[@CIT0008] Another gene associated with T2DM is the *CCR5* gene (accession number. 601373).[@CIT0009]--[@CIT0011]

Insulin initiates a wide range of growth and metabolic effects by binding to its receptor and activating the property of tyrosine kinase. These events cause phosphorylation of tyrosine kinase residues at the level of anchored proteins, which include insulin receptor substrate proteins (*IRS*)[@CIT0012] The phosphorylated IRS proteins are used as multi-position anchored proteins for different molecules that have homologous domains (SH2) or Src. The activity of these second SH proteins triggers the signaling cascade and results in the activity of several downstream filters that ultimately transmits the insulin message to the cellular vector pathways, thereby regulating cell differentiation, growth, survival and metabolism. In different studies, the frequency of *IRS1* polymorphisms in type 2 diabetic patients was more than control group.[@CIT0013]--[@CIT0015] The *IRS1* is a cytoplasmic substrate for insulin and also is a receptor for *IGF-1*, which plays a vital role in signaling. In recent studies, various roles in *IRS1* have been discovered, especially in patients with non-insulin diabetes mellitus. The *IRS1* gene polymorphisms were identified in 1993.[@CIT0016],[@CIT0017]

Chemokines are a large family of low molecular weight secretion proteins that play fundamental roles in physiological and pathophysiological processes such as angiogenesis, inflammation, atherosclerosis and autoimmune or allergic or infectious diseases.[@CIT0018],[@CIT0019] Their initial function is to regulate the migration of leukocytes at the concentration gradient, but they also play a role in the activation of the cells producing and secreting inflammatory mediators. These chemokines do their function by connecting to their G-protein receptors[@CIT0019] Excessive nutrition that has high levels of glucose and fatty acids can put stress on the pancreatic islets and insulin-sensitive tissues such as fat and liver and muscle, leading to the production and release of topical cytokines and inflammatory chemokines[@CIT0020] Among these inflammatory chemokines, *MCP-1, MIP-1α, MIP-1β, RANTES* (Regulated upon Activation, Normal T-cell Expressed, and Secreted) and *MCP-2* are mentioned. These chemokines interact with their receptors, triggering monocytes, as well as increasing the number of macrophages in the inflammation position. Chemokine receptors that can be mentioned include *CCR2* (CC chemokine receptor type 2), chemokine receptor MCP-1, and also chemokine receptors *CCR5, MIP-1α, MIP-1β, RANTES* and *MCP-2*[@CIT0021]

The *CCR5* gene is located at 3q21.3 position on the chromosome. The *CCR5* (59029A/G) polymorphism has been reported in the promoter region of the *CCR5* receptor gene[@CIT0022] Studies indicated that the *CCR5* (59029A/-) genotype results in increased expression of this receptor by peripheral blood mononuclear cells of individuals with this genotype, and therefore it is probably the genotype regulating the expression of the *CCR5* gene.[@CIT0009],[@CIT0020]

In this regard, the relationship between the *IRS1* (rs10498210) polymorphisms and *CCR5* (59029A/G) and the risk of T2DM have not been clearly and precisely indicated. Therefore, this study was conducted with the aim of investigating this relationship.

Methods {#S0002}
=======

Ethical statements {#S0002-S2001}
------------------

The study was ethically approved by the regional Ethics Committee of Sanandaj Branch, Islamic Azad University, and the study was conducted in accordance with the provisions of the Declaration of Helsinki.

Samples {#S0002-S2002}
-------

This research is a case-control study. During this study, the peripheral blood samples of 220 T2DM patients (fasting blood glucose higher than 150 mg/dL in two times) and non-200 diabetic subjects as control (fasting blood glucose less than 100 mg/dL in two times and gender- and ethnic-matched with the patients). Patients were selected randomly among individuals who referred to the Kurdistan Diabetes Centers in Kurdistan of Iran. Patients were selected in such a way that their diabetes was controlled (measured by HbAlc by the diabetes center). Inclusion criteria were diagnosed according to the American Diabetes Association diagnostic criteria (the blood glucose level of \>250 mg/dL or severe hyperglycemia). Written consent was received from the individuals and they were informed that sampling was for research purposes only.

DNA extraction {#S0002-S2003}
--------------

Extraction of DNA from the blood samples was performed by salt extraction method and DNA extraction was determined on agarose gel 1%. The isolated DNA was placed in separate microtubes and stored at −20°C until PCR was performed.

Molecular analysis {#S0002-S2004}
------------------

Determination of genotype was carried out by PCR-RFLP method and the primers ([Table 1](#T0001){ref-type="table"}) were used for replication of pieces. For the *CCR5* (59029A/G) polymorphism, the primers were taken from other articles but for *IRS1* (rs10498210) polymorphism was designed.Table 1The sequences of primers used in the study for *IRS1* (rs10498210) and *CCR5* (59029A/G)*IRS1*(rs10498210)*CCR5* (59029A/G)**Forward**5′-ACAGCCAAAAGGTAAAGCGT-3′5′-CCCGTGAGCCCATAGTTAAAACTC-3′**Reverse**5′-CCCTTCTCAAAGTACAGCATGT-3′5′-TCACAGGGCTTTTCAACAGTAAGG-3′**Product size**bp371bp258[^1]

PCR was performed in final volume of 20 μl using Sinagene PCR kit. The PCR cycles of the desired gene are presented in [Table 2](#T0002){ref-type="table"} separately. To ensure the correct replication of the desired piece, the PCR products were loaded on agarose gel 1.8%. and its quality was determined.Table 2PCR proliferation conditionsGenesInitial denaturationDenaturationAnnealingExtensionFinal extensionCycling condition**CCR5**94°C\
4 Min94°C\
30 Sec60°C\
60 Sec72°C\
60 Sec°72°C\
5 minRepeated for 34 Cycles**IRS1**94°C\
4 Min94°C\
30 Sec60°C\
60 Sec72°C\
60 Sec72°C\
5 minRepeated for 34 Cycles

In order to cut the desired region in the *CCR5* gene, the SduI enzyme was selected, which is detected as GGGCAC, and consequently, in the presence of the allele G in polymorphic position, enzyme cut the piece and in the presence of the allele A, the piece does not cut. The piece produced by PCR for the *CCR5* gene is a 258 bp base pair piece, and if the piece is cut, two pieces of 131 and 127 bases are created. To cut the desired region in the *IRS1* gene, the MaeII enzyme was selected, which is detected as ACGT. The PCR-proliferated piece is 371 bp. In the presence of the allele G in the polymorphic position, the enzyme has cut position, which results in two pieces of 229 and 142 bp, and in the presence of the allele A at the polymorphic position, the 371 bp piece is not broken, and totally one piece will remain. Then the digested products were loaded on 3% agarose gel and their genotypes were determined. Achieved frequencies significance between type 2 and control subjects were statistically analyzed using software popgene1.32 and by SPSS v20 and at significant level (*p*\<0.05).

Results {#S0003}
=======

This case-control study was performed on 420 unrelated individuals, including 220 patients with type 2 diabetic and 200 healthy controls. The allele frequencies of genotypes for all two SNPs were shown in [Table 3](#T0003){ref-type="table"}. In the population studied, the frequency AA, AG and GG genotypes of the *CCR5* gene were 120 (54.54), 84 (38.18) and 16 (7.27), respectively, among the patients and 81 (40.5), 70 (35) and 49 (24.5), respectively, in the control subjects. Also, in the *IRS1* gene it was as follows: among the 220 patients, the frequency of AG, AG and GG was 150 (68.18), 52 (23.63) and 20 (9.09), respectively, and also, among the 200 control subjects, the frequency of GG, AG and AA were 176 (88), 20 (10) and 4 (2), respectively. In patients, the allelic frequency of AA in both genes *CCR5* (OR (95% CI)=1.9 *P*=0.02) and *IRS1* (OR (95% CI)=2.62 *P*=0.02) were significantly more than controls. There was no significant association between AG or GG genotypes in with T2DM ([Table 3](#T0003){ref-type="table"}).Table 3Distribution of alleles and genotypes of *CCR5* (59029A/G) and *IRS*1 (rs10498210) genes among T2DM patients and healthy controlsGenes variantPatient\
n=220 (%)Control\
n=200 (%)Odds ratio (95% CI)*p*-value\*PcorrCCR5 (59029A/G)AA\
AG\
GG\
Alleles120 (54.54)\
84 (38.18)\
16 (7.27)81 (40.5)\
70 (35)\
49 (24.5)1.90 (1.04--3.39)0.020.03G\
A116 (26.36)\
324 (73.63)192 (96)\
208 (104)IRS1 (rs10498210)AA\
AG\
GG\
Alleles150 (68.18)\
52 (23.63)\
20 (9.09)176 (88)\
20 (10)\
4 (2)2.62 (1.61--4.89)0.0010.003G\
A92 (20.90)\
352 (80)28 (7)\
372 (93)0.31 (0.13--0.61)0.00010.0003[^2]

[Figure 1](#F0001){ref-type="fig"} shows the image of the agarose gel 3% for *CCR5* (59029A/G) polymorphism and also shows how to determine its genotype in ladder and size pieces as described above. Figure 1Genotype detection (59029A/G) *CCR5.*

[Figure 2](#F0002){ref-type="fig"} shows the image of the agarose gel 3% for *IRS1* (rs10498210) polymorphism and also shows how to determine its genotype in ladder and size pieces as described in \"Molecular analysis\" section. Figure 2Genotype detection (rs10498210) *IRS1.*

In this study, Hardy Weinberg equilibrium and heterozygosity were also studied for populations. The Hardy Weinberg equilibrium points to the fact that the genetic and genotype frequency is constant from generation to generation. The probability level in both type 2 diabetic and control subjects was greater than 0.05 for *IRS1* and *CCR5* genes, indicating a Hardy Weinberg equilibrium in these populations ([Table 3](#T0003){ref-type="table"}).

Heterozygosity for a gene position is defined as a frequency of heterozygote people for that position relative to the total population. For a gene position, if the heterozygosity is greater than 0.1, it is polymorphic and if it is more than 0.7, it is extremely polymorphic. Based on the results of this study, it was found that the difference between observed and expected heterozygosity for both studied polymorphisms was less than 0.1, so that the gene positions in this study are not polymorphic. In the next step, the mean of patient's clinical data which were collected from their files in Diabetes Center of Kurdistan was analyzed. The results of clinical data analysis are presented in [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}.Table 4Comparison of type 2 diabetic patients\' clinical data among different genotypes of polymorphism *IRS1* (rs10498210)Clinical dataAG-GGAA-GGAA-AG**Weight**0.1960.1070.536**Systolic blood pressure**0.9950.6330.700**Diastolic blood pressure**0.1540.0270.203**Total cholesterol**0.3220.0570.447**Triglyceride**0.5320.4430.958**Cholesterol HDL**0.4280.0000.000**Cholesterol LDL**0.2770.0980.288**Fasting blood glucose**0.9240.0290.016**HBA1C**0.4280.4530.768 Table 5Comparison of type 2 diabetic patients\' clinical data among different genotypes of polymorphism *CCR5* (59029A/G)Clinical dataAG-GGAA-GGAA-AG**Weight**0.6640.0750.156**Systolic blood pressure**0.0000.2110.086**Diastolic blood pressure**0.5400.8670.079**Total cholesterol**0.2630.0000.000**Triglyceride**0.0610.7710.219**Cholesterol HDL**0.1020.0770.536**Cholesterol LDL**0.4300.0000.000**Fasting blood glucose**0.0000.0000.220**HBA1C**0.7980.4560.401

Discussion {#S0004}
==========

This case-control study was performed on patients and healthy control from Iranian Kurdistan. The frequencies of genotypes and alleles for all two SNPs are shown in [Table 3](#T0003){ref-type="table"}. Results show that among patients and control subjects the allelic frequency AA, AG and GG genotypes of the *CCR5* gene were 120 (54.54), 84 (38.18) and 16 (7.27), and 81 (40.5), 70 (35) and 49 (24.5), respectively. Also, in the *IRS1* gene it was as follows: among the 220 patients, the allelic frequency of AG, AG and GG was 150 (68.18), 52 (23.63) and 20 (9.09), respectively, and also, among the 200 control subjects, the frequency of GG, AG and AA was 176 (88), 20 (10) and 4 (2), respectively. The frequency of AA genotype in patients in both genes *CCR5* (OR (95% CI)=1.9 *P*=0.02) and *IRS1* (OR (95% CI)=2.62 *P*=0.02) was significantly more than controls. There was no significant association between AG or GG genotypes with T2DM ([Table 3](#T0003){ref-type="table"}). Also, weight, systolic blood pressure, diastolic blood pressure, total cholesterol, triglyceride, cholesterol HDL, cholesterol LDL, fasting blood glucose and HBA1C were significantly higher in the patients\' group when compared to the control group ([Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}).

McDermott et al., who found for the first time the A/G polymorphism in the 59029 base pair in the promoter region of this gene, reported that both alleles of this polymorphism are common in societies, and the allelic frequency of 59029A, depending on the ethnic population, varies between 43% and 68%. Differences in the frequency of allelic A in different communities can be due to genetic differences between populations.[@CIT0022],[@CIT0023]

According to the results, it is possible that the *CCR5* genotype (AA 59029) plays an important role in the pathogenesis of T2DM. Studies indicated that the *CCR5* (59029A/-) genotype results in increased expression of *CCR5* by peripheral blood mononuclear cells of individuals with this genotype. In a study by Dytfeld et al., the expression of *CCR5* receptor expression was measured on the peripheral blood mononuclear cells of type 2 diabetics, and it was determined that the expression of *CCR5* receptor on the cell surface in type 2 diabetic patients is also increasing, and high expression of this receptor can be considered as an indicator of atherosclerosis in diabetic people[@CIT0024]

Given the evidence of T2DM which was recently provided and type 2 diabetes introduced as an inflammatory disease, it can be expected that high expression of this receptor (*CCR5*) on the level of single-cellular cells of the blood increases inflammatory responses and increases the risk of T2DM. However, in order to confirm with certainty the existence of such a connection, further studies in a wider population are needed.

Regarding the role of *IRS1* gene in the pathway of insulin signaling and the negative effect of rs10498210 polymorphism on the performance of this protein, it can be expected that this polymorphism is present in the etiology of T2DM. Recent studies have indicated that *IRS1* plays an important role in regulating insulin secretion in beta cells of the pancreas. It has been shown that glucose-stimulated insulin secretion may be triggered by the autocrine activation of insulin signaling pathway, including insulin receptor phosphorylation, tyrosine phosphorylation in *IRS1* and the activation of *PI3-Kinase*.

Putting together these data leads to the hypothesis that a single molecular impairment in the pathway of insulin signaling, including an incomplete interaction between *PI3-Kinase* and *IRS1*, may lead to insulin resistance, as well as insulin secretion defect.

So far, there has been a weak link between this polymorphism and T2DM, especially in obese people, but few studies have reported the association between this polymorphism and diabetes. In general, a variety of allele A in *IRS1* frequencies have been reported in many studies, and controversial reports have revealed the association of this polymorphism with type 2 diabetes[@CIT0025] Finally, according to the results of this study, it can be concluded that the probability of positive effect of allele A on studied polymorphisms *IRS1* (rs10498210) and *CCR5* (59029A/G) increase the risk of T2DM. Also, clinical data from diabetic patients suggest that the allele A from both studied polymorphisms plays a positive role in increasing the risk of cardiovascular disease in type 2 diabetic patients. However, to be sure about the impact of these polymorphisms on T2DM, it is necessary to study a larger population. It is also possible to compare the clinical data of patients with healthy subjects and examine the effect of these two polymorphisms on the clinical data of these two groups and more effectively to study the role of these polymorphisms in increasing the risk of disease cardiovascular disease. The two studied genes in current study are associated with insulin resistance based on two different mechanisms. *IRS1* plays a role in the insulin signaling pathway in its target tissues and *CCR5* plays a role in the inflammation pathway in fatty tissues and beta cells in the pancreas. By simultaneous examination of these two genes and the effect of their different variants together, in type 2 diabetic patients, greater recognition of the importance of each of these pathways in the pathogenesis of T2DM can be obtained.

Conclusion {#S0005}
==========

The presence of AA homozygote alleles in both loci of *IRS1* (rs10498210) and *CCR5* (59029A/G) genes increased the risk of T2DM. There was no significant association between AG or GG genotypes in with T2DM.
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[^1]: **Abbreviation: **T2DM, type 2 diabetes mellitus.

[^2]: **Abbreviation: **T2DM, type 2 diabetes mellitus.
